GlassScriptPhysician profile
Monika Schaub Smith
NPI 1023632510
$3,404.53
in general payments reported to CMS, 2019-2025
31 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,032 · 2022: $992 · 2023: $611 · 2024: $296 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.79 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $280.41 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $250.71 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $239.15 | 2021 | |
| Novo Nordisk INC | $191.22 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $171.46 | 2023-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $169.89 | 2022-2025 | Auvelity |
| Pfizer INC. | $167.35 | 2023-2025 | |
| Amgen INC. | $148.60 | 2021-2024 | Otezla, Repatha, Evenity |
| Supernus Pharmaceuticals, INC. | $56.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.09 | 2021-2023 | Trintellix |
| Mannkind Corporation | $47.68 | 2025 | |
| Jazz Pharmaceuticals INC. | $42.02 | 2021-2022 | |
| Lundbeck LLC | $40.97 | 2022-2023 | Rexulti |
| Biogen, INC. | $36.25 | 2022-2024 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $35.11 | 2021-2023 | Wellbutrin, Aplenzin |
| Glaxosmithkline, LLC. | $33.37 | 2023 | Arexvy, Shingrix |
| Avanir Pharmaceuticals, INC. | $30.99 | 2021 | |
| Csl Behring | $25.09 | 2024 | Kcentra |
| Otsuka America Pharmaceutical, INC. | $22.61 | 2022 | |
| Corium, LLC | $22.23 | 2022 | |
| Baxter Healthcare | $20.32 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Dexcom, INC. | $19.57 | 2023 | Dexcom G6 Transmitter |
| Impel Pharmaceuticals INC. | $18.92 | 2022 | |
| Viatris Specialty LLC | $17.75 | 2025 | Yupelri |
| Acacia Pharma INC | $17.41 | 2022 | |
| Exact Sciences Corporation | $16.41 | 2025 | The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $14.33 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.77 | 2024 | |
| Gilead Sciences, INC. | $13.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.87 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monika Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.